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Results: We show that 60% of index cases with heritable BPD enrolled at 10 European or US centres were
annotated with HPO terms indicating abnormalities in organ systems other than blood or blood-forming tissues,
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harbour variants in ACTN1 also clustered closely, even though diagnosis of this recently described disorder was not
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Bleeding and platelet disorders (BPD) are a heterogeneous
group of rare diseases caused by abnormalities of coagula-
tion factors, platelets or blood vessel walls. Although in
most cases the major clinical feature is abnormal bleeding,
BPD are frequently associated with phenotypes in other
organ systems, particularly the immune system (for ex-
ample, Wiskott-Aldrich syndrome (WAS, ORPHA906)),
skeleton (for example, Thrombocytopenia with Absent
Radius syndrome (ORPHA3320)), eye (for example,
Hermansky-Pudlak Syndrome (HPS, ORPHA79430)) and
kidney (for example, MYH9-related disorder (MYH9-RD,
ORPHA182050)). BPD may be inherited as autosomal re-
cessive, autosomal dominant, X-linked, or complex traits.
Collectively, BPD represent a significant diagnostic and
management challenge to health care systems [1].
Diagnosis of BPD currently requires clinical evaluation,
then tests such as coagulation factor activity and platelet
function assays [2,3]. However, for mild BPD, this enables
diagnosis to the level of a defective coagulation factor or a
platelet pathway in only 40% to 60% of cases [4,5]. The
proportion of cases with BPD that receive genetic diagno-
sis is even lower [6], partly because the genetic basis of
most BPD remains unknown, particularly for prevalent
sub-groups such as platelet secretion defects [5]. Even
for BPD with a known genetic basis, diagnosis may
not be possible if phenotype tests are insufficiently spe-
cific to point towards relevant genes. Moreover, many
BPD with causal variants in the same gene are clinically
heterogeneous, as illustrated by MYH9-RD in which
macrothrombocytopenia is a consistent feature, but neu-
trophil Döhle-like inclusions, renal impairment, deafness
and cataracts are variable [7,8]. High throughput sequen-
cing (HTS) has the potential to circumvent these limita-
tions by providing a diagnostic tool for genetic diagnosis
and by enabling gene discovery to increase the repertoire
of disorders for which genetic diagnosis is possible.
Analysis of large case collections recruited through con-
sortia of investigators and technologies such as HTS assist
discovery of rare BPD genes [9,10]. However, gene discov-
ery additionally requires analysis of shared data through
systematic phenotype coding to identify similarities be-
tween unrelated cases. Phenotype coding also facilitates
creation of clinical registries, genotype-phenotype data-
bases and biobanks. Examples of coding systems include
the World Health Organization International Classification
of Diseases (ICD) [11], which provides a post-diagnosis
classification of disease organized by organ system that is
unsuitable for coding rare genetic diseases particularly
those that affect multiple organs. The International
Health Terminology Standards Development Organisation
Systematized Nomenclature of Medicine Clinical Terminology
(SNOMED-CT) [12] is an alternative system, but is not
optimised for laboratory results and has greater emphasison specific diseases rather than phenotypes. Platforms
such as Online Mendelian Inheritance in Man (OMIM)
[13] and Orphanet [14] provide descriptions of known
genetic disorders but do not utilise systematic phenotype
terms. The Bleeding History Phenotype Ontology [15] is a
hierarchical ontology system that may enable phenotypic
similarities between some cases with BPD to be resolved.
However, this ontology has a limited repertoire of pheno-
typic terms outside those immediately pertinent to bleed-
ing. Moreover, there are no terms for the results of
laboratory tests such as light transmission aggregation or
dense granule secretion. These are essential for the accur-
ate phenotypic description of platelet function disorders,
which are the largest single group of BPD of unknown
genetic basis.
The Human Phenotype Ontology (HPO) project is an
international initiative to support the phenotypic annota-
tion of genetic disorders available under an open-source li-
cence [16]. The HPO version 887 contains a set of 10,371
terms that describe abnormalities of human phenotype
and 13,556 relations between the HPO terms organised
hierarchically through is-a relations [17]. For example,
‘thrombocytopenia is-a abnormal platelet count is-a ab-
normality of thrombocytes’. This enables phenotypes to
be described using a standardised and controlled vocabu-
lary with greater detail and flexibility than other coding
systems. The HPO has previously been applied to diseases
using phenotypic terms from Orphanet and OMIM [18]
but it has not previously been used to describe and com-
pare phenotype data from individual cases. Systematic
comparison of phenotype data from individual cases as-
sists gene discovery because clusters of cases with similar
phenotypes are likely to share defects in the same gene or
interacting set of genes [19].
The BRIDGE-BPD study [20] is a multicentre, observa-
tional consortium study that aims to identify causal gene
defects in cases with BPD of unknown aetiology by deep
multi-system phenotyping and HTS. We report the re-
sults of Stage 1 of the BRIDGE-BPD study in which we
develop new HPO terminology to facilitate annotation of
BPD phenotypes in 707 BPD cases recruited at 10 European
and US centres. We show for the first time how HPO an-
notation can be used to describe the phenotypes of indi-
vidual cases within a large rare disease collection and how
a novel statistical clustering approach using HPO data
guides gene discovery.
Methods
Study overview and enrolment criteria
The target population for the BRIDGE-BPD study com-
prises children and adults with disorders of platelet num-
ber, volume, morphology or function or with pathological
bleeding that cannot be explained by standard laboratory
tests. To ensure enrolment of cases with a high likelihood
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such as a BPD from an early age, a BPD that is part of a
syndromic disorder or a family history of a BPD. Cases
with an acquired BPD (Table 1) or a known genetic BPD
are excluded unless they display bleeding or laboratory
features that cannot be explained by this diagnosis alone.
For example, a case with haemophilia A and unexplained
thrombocytopenia is considered eligible on the basis of
thrombocytopenia. Most cases had already been investi-
gated within research and specialist clinical diagnostic
facilities, maximising exclusion of acquired or known
genetic BPD. The BRIDGE-BPD study is approved by
a UK Research Ethics Committee (Cambridgeshire 1
Research Ethics Committee 10/H0304/66) and appropriate
national ethics authorities for non-UK enrolment centres
(Additional file 1). All study procedures were performed
after the participants provided informed written consent
and were in accordance with the Declaration of Helsinki.
Sequence data for cases who provided consent for public
access have been deposited at the European Genome-
Phenome Archive (EGAS00001001172).
Recruitment of cases and collection of phenotype data
Index cases and pedigree members were identified by
screening clinic lists, case notes and local registries. Po-
tential participants were checked for eligibility and were
invited to give informed written consent. Demographic
and clinical data, laboratory test results and pedigree re-
lationships were recorded on a case report form.
BRIDGE-BPD database
Pseudonymised demographic and clinical data were trans-
ferred to electronic data capture pages usually as quantita-
tive or categorical variables but with a minority as free text
to maintain detail. Bleeding symptoms were recorded as
numerical severity scores for the 12 major symptoms within
the MCMDM-1 VWD Bleeding Assessment Tool [21], or
as the terms ‘yes’ or ‘no’ for each symptom (Additional
file 2). Laboratory test results were recorded as quantitativeTable 1 Eligibility criteria for BRIDGE bleeding and platelet d
Inclusion criteria E
Platelet count less than 100 × 109/L or greater than 400 × 109/L, or A
Mean platelet volume less than 6 fL or greater than 12 fL, or U
Reproducible abnormal platelet function test results, or Im
Abnormal platelet morphology by light or electron microscopy, or H
Pathological bleeding of unknown aetiology, and M
Considered by referring clinician to be of genetic aetiology B
Th
A
Sp
Uvariables, except for tests such as platelet light transmission
aggregation (LTA) and ATP secretion, which were recorded
as ‘normal’ or ‘abnormal’ according to the interpretation
of the enrolling clinician. Platelet morphology determined
by light or electron microscopy was recorded as free text.Development of HPO terminology for BPD
In order to ensure accurate annotation of the bleeding and
platelet phenotype, 80 terms and associated is-a relation-
ships were added to HPO [17], in parallel with develop-
ment of hpoPlot, a new free software tool that summarises
HPO codes of a set of cases, released on the Comprehensive
R Archive Network [22]. The HPO modifications were
predominantly within the abnormality of blood and blood-
forming tissue leading class and its constituent classes
‘abnormality of thrombocytes’, ‘abnormal bleeding’, ‘abnor-
mality of coagulation’ and ‘abnormal thrombosis’. Some
terms required creation of a new ‘abnormal platelet morph-
ology’ class (Additional file 3). Many terms within ‘abnor-
mality of blood and blood-forming tissue’ overlap with
other system-specific HPO leading classes, particularly
‘abnormality of the immune system’ (Additional file 4).Automated and suggested HPO terms
To improve the reliability and efficiency of HPO coding,
cases were annotated with relevant terms automatically
for abnormal bleeding symptoms or abnormal categorical
laboratory test results and for some numerical laboratory
test results, if outside a gender-specific reference interval.
For the remaining laboratory test results, suggested HPO
terms were presented for manual confirmation. This was
necessary to prevent inappropriate coding if a laboratory
test result was abnormal because of a co-morbidity or if
the reference interval was not applicable because the case
was a child or pregnant. HPO terms for other clinical or
laboratory abnormalities could be selected through expan-
sion of parent HPO terms or by searching for a specific
HPO term.isorders study
xclusion criteria
cquired bleeding or platelet disorders, including any of the following:
se of any medication known to affect platelet function or cause bleeding
mune thrombocytopenia
IV infection
alignancies, particularly those affecting haemopoiesis
one marrow aplasia
rombotic thrombocytopenic purpura/ Haemolytic-uremic syndrome
cute viral infection
lenomegaly
raemia or hepatic failure
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We define the relative information content (IC) of HPO
terms on the basis of their rarity within the BPD case
collection. Measures of phenotypic similarity between a
pair of individuals, represented as two sets of HPO terms,
are then determined by the overall rareness of the pair’s
shared terms [23]. The IC of term t is given by
IC tð Þ ¼ − logpt ;
where pt is the frequency of the term in the BPD collec-
tion. The similarity between two terms, s and t, is defined
as
sim s; tð Þ ¼ max
v ∈anc sð Þ∩anc tð Þ
IC vð Þ;
where anc(x) denotes the ancestor terms of x, that is, the
terms {y|x ‘is - a’ y}. The similarity between two cases rep-
resented as two sets of terms, Da and Db, is given by
sim Da;Dbð Þ ¼ 12 Daj j
X
s∈Da
max
t∈Db
sim s; tð Þ
þ 1
2 Dbj j
X
s∈Db
max
t∈Da
sim s; tð Þ:
This definition ensures symmetry of the similarity meas-
ure. A scale-independent measure of phenotypic dissimi-
larity was also computed between two cases a and b with
respect to the rest of the collection:
dist a; bð Þ ¼ 1
2
X
i∈ a;bf g
X
j ∉ a;bf g
1sim Di; Djð Þ≤sim Da;Dbð Þ;
where Da is the set of HPO terms associated with case a.
The rank distance among a set Z of more than two cases
is given by the mean over all pairwise distances:
dist Zð Þ ¼ Zj j
2
 −1 X
a;b∈Z;a≠b
dist a; bð Þ:
To evaluate the phenotypic similarity of a group of cases,
Z, with respect to a containing collection, a one-tail Monte
Carlo P value for testing whether the distance between
cases in Z was less than what would be expected by chance
in a similar size group was computed as:
1
Wj j
X
W∈W
1dist Wð Þ≤ dist Zð Þ
where W is a set of 250,000 subsets of |Z| index cases
drawn at random from the entire collection. Although
these P values are marginally uniform under the null,
there may be a small correlation between them because
the same data are reused in each set of permutations.
However, if |Z| is small relative to the total sample size,
the correlation should be negligible.HPO-based clustering of cases
Unsupervised clustering of unrelated BPD cases was per-
formed by applying the Partitioning Around Medoids
(PAM) algorithm [24], to a square distance matrix M in
which the ath row and bth column was set to -sim(Da, Db).
Affected relatives were excluded to ensure that the ensu-
ing clusters did not depend on enrolment patterns of the
affected relatives of particular index cases. The discrimin-
atory power of HPO nodes shared by cases within each
cluster was determined by performing a Fisher exact test
on the contingency table containing the number of cases
inside/outside the cluster vs the number of cases with/
without the HPO node. Each cluster was then summarised
by the HPO node having the smallest P value overall and
up to two nodes from other distinct lineages in the HPO
graph having a P value smaller than 10-3. When there
were multiple nodes within a lineage fulfilling these cri-
teria, only the most significant node was retained.
Whole exome sequencing and variant reporting
Genomic DNA was isolated from venous blood or saliva
obtained from the cases at enrolment or from archived
samples. DNA library capture was performed using
ROCHE NimbleGen SeqCap EZ 64 Mb Human Exome
Library version 3.0 (ROCHE NimbleGen, Inc., Madison,
WI, USA). The libraries were sequenced on an Illumina
Hiseq 2000 instrument (Additional file 5 [25-27]). In order
to filter for technical artefacts and variants unlikely to be
pathogenic, variants were excluded from further analysis
if they fulfilled any of the following criteria: (1) variant
allele frequency >0.1% in any of the reference cohorts
(Additional file 6); (2) variant not predicted to alter pro-
tein by snpEff 3.4 [28]; (3) variant not present in other
affected pedigree members recruited to BRIDGE-BPD;
(4) <3 reads supporting the alternate allele; (5) allele
count >1 among 20 in-house whole-genome sequenced
controls; (6) overall allele count >20 including exomes
from other BRIDGE projects.
Assigning causality to rare variants in known BPD genes
In order to assist analysis of variants identified in the
BPD cases, we utilised the ThromboGenomics platform
version 1.0 list of 49 genes that have already been linked
to human platelet or coagulation disorders (Additional
file 7) [29,30]. Rare variants in ThromboGenomics genes
were classified using the following definitions that are
consistent with current EuroGentest guidelines for assign-
ing pathogenicity to variants [31]: (1) Pathogenic variant
(PV): a variant present in the Human Genome Mutation
Database (HGMD) [32] with a matched phenotype to the
BRIDGE-BPD case; (2) Likely pathogenic variant (LPV):
a non-HGMD variant in a gene for which previously re-
ported cases have a matched phenotype with the BRIDGE-
BPD case; (3) Variant of unknown significance (VUS): all
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that met the criteria for a PV or LPV in an individual case
were reclassified as a VUS if there was an inconsistent rela-
tionship with phenotype and mode of inheritance in other
cases within the BRIDGE-BPD collection.
Results
Characteristics of the study collection
In Stage 1 of the BRIDGE-BPD study, 648 index cases and
59 affected pedigree members (414 female, 293 male) were
recruited at 10 enrolment centres (Figure 1). WES has
been completed for 519 cases (Additional file 8).
Platelet count (PLT) was recorded for 639 of the 648
index cases, of which 140 (21.9%) had PLT <100 × 109/L
and 53 (8.3%) had PLT >400 × 109/L. Mean platelet vol-
ume (MPV) was recorded for 460 index cases of which
one (0.2%) had MPV <6 fL and 91 (19.8%) had MPV >12
fL. Since some automated cytometers do not enumerate
the MPV in blood samples with large platelets, enrolling
clinicians were able to record whether large platelets were
visible by light or electron microscopy. This identified
a further 56 index cases with large platelets. Bleeding
occurred across the range of platelet counts and volumes
(Figure 2A,B). A total of 330 (50.9%) index cases had ab-
normal platelet morphology, defined as abnormal struc-
ture or size determined by light or electron microscopy
(Additional file 9).
After excluding cases with PLT <100 × 109/L or an un-
measured PLT in which reliability of LTA results cannotFigure 1 Recruitment to the BRIDGE-BPD study by enrolment
centre. Gender stratified recruitment to the BRIDGE-BPD Consortium
study is shown according to enrolment centre. (A) University of
Leuven, Leuven, Belgium; (B) Royal Free NHS Trust, London, UK;
(C) Centre de Référence des Pathologies Plaquettaires, Pessac, France;
(D) Imperial College Healthcare NHS Trust, London, UK; (E) Cambridge
University Hospitals NHS Foundation Trust, Cambridge, UK;
(F) University Hospitals Bristol NHS Foundation Trust, Bristol, UK;
(G) Haematological Laboratory, Trousseau Children’s Hospital and
INsermU1009, Paris, France; (H) Children’s Hospital of Philadelphia,
Philadelphia, USA; (I) Great Ormond Street Hospital For Children NHS
Trust, London, UK; (J) Charité Universitätsmedizin, Berlin, Germany.be guaranteed, there were 428 (66.0%) index cases with
an LTA test result recorded for at least one agonist. A
total of 196/428 (45.8%) index cases had two or more
and 80/428 (18.7%) had three or more agonist responses
that were classified as abnormal by the enrolling clin-
ician (Figure 2C).
Clinical phenotype and HPO coding
The presence or absence of up to 10 bleeding symptoms
for males and 12 bleeding symptoms for females was re-
corded for 528 index cases. Among the 197 male cases,
45 experienced four or more different bleeding symptoms
and 12 had six or more symptoms. Among the 331 female
cases, 58 experienced six or more different bleeding symp-
toms and nine had eight or more symptoms. The most
common bleeding symptoms were cutaneous bleeding
(343 index cases), bleeding from minor wounds (231 index
cases) and epistaxis (215 index cases; Figure 3).
The median number of HPO terms annotated to each
case was 7.5 (range 1 to 23; Figure 4A). All index cases
were annotated with one or more HPO term from the
‘abnormality of blood and blood-forming tissue’ leading
class. Of the 648 index cases, 387 (59.7%) were also an-
notated with one or more HPO term outside of ‘abnor-
mality of blood and blood-forming tissue’ after excluding
terms that are ‘descendants’ of both the ‘abnormality of
blood and blood-forming tissue’ class and other lead-
ing classes (Additional file 4 and Figure 4B). The most
common other HPO terms described abnormalities of
the nervous system (149 index cases), immune system
(107 index cases) and skeletal system (102 index cases).
When index cases were grouped by abnormality in each
other organ system, the frequencies of terms relevant
to thrombocytopenia, thrombocytosis, bleeding, platelet
morphology and platelet aggregation reflected the overall
proportions of these terms in the collection for most
organ systems. However, in cases with terms relevant to
the nervous system and growth these terms showed sig-
nificantly different distributions (P <0.05 after Bonferroni
correction, which allows for dependence between tests in
addition to multiplicity; Figure 4B).
Clustering of cases using HPO
We performed unsupervised clustering of the HPO-encoded
phenotype data in order to obtain an undirected charac-
terisation of different subgroups within the heterogeneous
BPD collection and assess whether particular sets of HPO
terms tended to co-occur among cases in these groups.
The 648 unrelated index cases were partitioned into
30 clusters ranging in size from five to 36 cases. Clinically
recognisable subgroups included ‘Impaired epinephrine-
induced platelet aggregation, Impaired ADP-induced plate-
let aggregation’ (Additional file 10, cluster 18 and Figure 5)
which is a frequently reported pattern of abnormality in
AC
B
Figure 2 Platelet characteristics of the BRIDGE-BPD study index cases. (A, B) The relationship between PLT and MPV in femtolitre (fL) in male and
female index cases. The crosses indicate index cases with greater than four (males) or greater than five (females) bleeding symptoms. The circles
indicate index cases with fewer bleeding symptoms. NA: not available - cases in which large platelets were identified by the enrolling clinician
but the MPV was not recorded. (C) Heat map showing the results of light transmission aggregation tests with the indicated activating agonists,
classified as normal or abnormal by the enrolling clinician. The numbers in brackets indicate the number of index cases tested for each agonist.
Cases are ordered by the number of abnormal or not done results across all six agonists. The bar above the heat map is colour-coded to indicate
the enrolment centre for each case.
Figure 3 Bleeding symptoms of BRIDGE-BPD study index cases. Heat map showing the bleeding symptoms recorded for the BRIDGE-BPD index
cases. The numbers in brackets indicate the number of index cases reporting each bleeding symptom. Cases are ordered by the number of bleeding
symptoms. The bar above heat map is colour-coded to indicate the enrolment centre for each case.
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Figure 4 HPO terms coded in BRIDGE-BPD study index cases. (A) Bar plot indicating the number of human phenotype ontology (HPO) terms
annotated to the index cases. (B) Heat map showing the relative frequencies of HPO terms pertinent to abnormalities in platelets and bleeding
symptoms and in other organ or disease areas in the BRIDGE-BPD index cases. The numbers in the brackets and the barplots indicate the number
of index cases with at least one HPO term pertinent to abnormality in the organ or disease area after removal of overlapping terms. *indicates
that the distribution of terms pertinent to enrolment for a particular column is significantly different compared to the sum (along rows) of all
other columns (P value <0.05 after Bonferroni correction by chi-squared test). The columns are ordered by the number of cases having a term in
each leading class.
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ously as a Gi-pathway defect [33]. A further prominent
cluster was ‘Autism spectrum disorder, Thrombocytosis,
Decreased mean platelet volume’ (Additional file 10, clus-
ter 29 and Figure 5) illustrating an increasingly recognised
association between platelet abnormalities and neuro-
logical disorders [34].
A new approach to gene discovery using HPO-encoded
phenotype data
In order to resolve causal gene variants from the numer-
ous candidates in a rare disease study in which geneticheterogeneity is expected, it is typically assumed that
cases with causal variants in a gene or set of related genes
have similar phenotypes. We therefore hypothesised that
cases with rare coding variants in a disease gene would
tend to cluster strongly on the basis of their HPO-encoded
phenotypes. To validate this approach, phenotype close-
ness was first computed within the pedigree groups
without provisional syndromic diagnoses recruited to the
BRIDGE-BPD study, who are expected to share a causal
gene variant. The phenotypic similarity P values corre-
sponding to the 50 pedigrees were significantly enriched
near zero (40 had P <0.05 (2.5 expected under the null),
Cluster 18 Cluster 29
Figure 5 Phenotype clusters 18 and 29. Illustrative subgraphs of the HPO showing terms for the phenotype clusters 18 (15 cases) and 29 (16 cases).
Arrows indicate direct (solid) or indirect (dashed) is a relations between terms in the ontology. DMPV: decreased mean platelet volume; PA:
phenotypic abnormality; Plt-agg: platelet aggregation abnormality.
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0.33 and P = 0.42). Additionally, we validated our approach
by assessing the phenotypic closeness of groups of index
cases with provisional syndromic diagnoses made through
clinical evaluation, as these are likely to have pertinentFigure 6 Phenotype similarity clustering of cases according to HPO terms.
members of pedigrees, cases with classical syndromes and cases with var
hierarchical clustering within each class and P values of phenotypic sim
showing the distribution of P values.variants in a set of related genes. Index cases enrolled with
provisional clinical diagnoses of Gorham-Stout syndrome
(n = 7) (ORPHA73), HPS (n = 8), pseudohypoparathyroid-
ism type Ib (n = 4) (ORPHA94089), Roifman syndrome
(n = 4) (ORPHA353298) and WAS (n = 3) also demonstratedHeat map showing pairwise phenotypic similarity among affected
iants in ACTN1. The groups are ordered through complete-linkage
ilarity are shown in a scatterplot superimposed over a histogram
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A meta-analysis using Fisher’s method to assess whether
these groups clustered closely together as a whole yielded
a P value that is less than the numerical resolution of the
analysis software. These data demonstrate that despite oc-
casional anomalies, BPD cases in which a common genetic
basis is likely tend to cluster on the basis of their HPO
terms.
Cases with variants in ACTN1 cluster strongly on the basis
of their HPO terms
We applied our approach under an autosomal dominant
model and discovered that the gene for which cases had the
strongest phenotype similarity was ACTN1 (P= 3.4 × 10-8).
Causal variants in ACTN1 have been identified in 18 re-
cently reported pedigrees with a phenotype that comprises
mild bleeding and macrothrombocytopenia with no other
syndromic features [35-37]. Consistent with these previ-
ous descriptions, amongst the 21 index cases and three
pedigree members with ACTN1 variants in the BRIDGE-
BPD analysis, 23/24 (96%) displayed thrombocytopeniaTable 2 Rare variants identified in ACTN1
Case Transcript variant
ENST00000394419
Protein variant
ENSP00000377941.4
HGMD variant C
B200726 14:69392385 A/C F37C No L
B200207 14:69392358 C/T R46Q Yes P
B200209 P
B200212 P
B200254 P
B200735 P
B200746 14:69392359 G/A R46W No L
B200197 14:69392344 G/C Q51E No L
B200836 14:69387750 C/T V105I Yes P
B200837a P
B200671 14:69371375 C/T E225K Yes P
B200716 P
B200398 14:69369274 C/T V228I No L
B200280 14:69358897 C/T R320Q No L
B200281a L
B200835 14:69352254 C/T A425T No V
B200283 14:69349768 A/G L547P No L
B200048 14:69349648 G/A A587V No V
B200284 14:69346749 G/T T737N No L
B200285a L
B200741 14:69346747 G/A R738W Yes P
B200745 P
B200750 14:69346746 C/T R738Q No L
B200414 14:69346704 C/G R752P No L
aAffected family member.and 22/24 (92%) large platelets (Table 2). HPO-based clus-
tering of this group occurred irrespective of whether the
ACTN1 variants were classified as PV, LPV or VUS. Clus-
ter 1 (Additional file 10) was significantly enriched for var-
iants in ACTN1 (Fisher’s exact test P value 1.79 × 10-5).
Pertinent and non-pertinent rare variants in MYH9
We also assessed the HTS and data analysis pipelines
with the autosomal dominant disorder MYH9-RD. We
selected this disorder because previous descriptions of
MYH9-RD suggested that cases are usually readily iden-
tified clinically and were unlikely to have been recruited.
Despite this, we identified nine different MYH9 missense
variants in 13 unrelated BPD cases and one pedigree
case. These included seven index cases with rare variants
classified as PV or LPV and six index cases with VUS. In
order to investigate whether HPO annotation and cluster
analysis would have enabled detection of these cases as a
distinct phenotype group we explored the HPO terms
that had been assigned to these cases. The seven index
cases with PV or LPV in MYH9 included six cases withlassification PLT, ×109/L MPV, fL, and/or presence
of macrothrombocytes
Bleeding
phenotype
PV 57 18.1, macrothrombocytes None
V 53 >13, macrothrombocytes None
V 76 >13, macrothrombocytes Mild
V 98 >13, macrothrombocytes None
V 34 >13, macrothrombocytes None
V 52 12.0, macrothrombocytes None
PV 96 15.2, macrothrombocytes None
PV 113 >13, macrothrombocytes Mild
V 53 NA, macrothrombocytes None
V 75 NA, macrothrombocytes None
V 97 13.7, macrothrombocytes Mild
V 82 15.0, macrothrombocytes None
PV 31 15.4, macrothrombocytes Mild
PV 108 15.1, macrothrombocytes Mild
PV 111 13.9, macrothrombocytes None
US 50 10.0, no macrothrombocytes Mild
PV 91 13.3, macrothrombocytes Mild
US 390 NA, no macrothrombocytes Mild
PV 60 16.1, macrothrombocytes Mild
PV 48 16.8, macrothrombocytes Mild
V 94 12.9, macrothrombocytes None
V 70 14.5, macrothrombocytes None
PV 106 14.0, macrothrombocytes None
PV 121 11.4, macrothrombocytes Mild
Westbury et al. Genome Medicine  (2015) 7:36 Page 10 of 15terms indicating macrothrombocytes, six with terms indi-
cating thrombocytopenia and one with neutrophil Döhle-
bodies but none with other recognised features such
as renal impairment, sensorineural deafness or cataract
(Table 3). The seven index cases with PV or LPV clustered
closely together based on the HPO terms (P = 0.005) while
the six index cases with VUS did not cluster (P = 0.684).
However, the 13 index cases as a whole did not cluster
strongly based on their HPO phenotypes (P = 0.363) due
to the dilution of PV with VUS. This observation high-
lights the need for improved algorithms for selecting can-
didate variants based on predictions of pathogenicity but
also supports our stringent approach for assigning causal-
ity to variants in known genes.
Variant identification in the ThromboGenomics gene list
The BRIDGE-BPD HTS and data analysis pipelines were
tested by evaluating coding variants in the ThromboGe-
nomics list of known genes linked to autosomal recessive
or X-linked recessive BPD. Since cases with BPD of known
genetic aetiology were excluded from enrolment, we pre-
dicted that causal variants in the ThromboGenomics genes
would be uncommon. Consistent with this, we identified
PV in only two ThromboGenomics genes that completely
explained the phenotype of one case with HPS3 and two
cases with WAS. Further cases with PV in F9 and in F8
displayed reduced FIX and FVIII activity, respectively, that
were explained by the observed PV. However, these cases
also displayed abnormal platelet function indicating that
the PV only partially explained the phenotype. Three cases
had variants classified as LPV in ThromboGenomics genes,
which cannot be considered causal for the BPD phenotypeTable 3 Rare variants identified in MYH9 and validated by Sa
Case Transcript variant
ENST00000216181
Protein variant
ENSP00000216181
HGMD variant Cla
B200760 22:36744995 G/A S96L Yes PV
B200771 22:36705438 C/A D578Y No VUS
B200423 22:36696237 G/A A971V No VUS
B200024 22:36691696 A/G S1114P Yes VUS
B200245 VUS
B200243 22:36691115 G/A R1165C Yes PV
B200594 PV
B200595a PV
B200614 22:36688151 C/T D1409N No VUS
B200752 VUS
B200855 VUS
B200208 22:36688106 C/T D1424N Yes PV
B200010 22:36685249 G/C S1480W No VUS
B200244 22:36678800 G/A R1933X Yes PV
Other MYH9-RD characteristics sought were the presence of Döhle inclusions, catar
aFather of B200594.without further confirmatory investigations (Table 4). A
further 10 index cases had variants classified as VUS in
ThromboGenomics genes because there was no plausible
association between the gene and phenotype (Additional
file 11). This group included cases with variants in coagu-
lation factor genes who had normal levels of coagulation
factors.
Discussion
Heritable BPD are individually rare but collectively com-
mon diseases that have heterogeneous clinical character-
istics. This clinical complexity, genetic heterogeneity and
the large number of candidate genes for BPD has previ-
ously hampered gene discovery. In this exploratory Stage
1 of the BRIDGE-BPD study, we first enhanced HPO
terminology to enable standardized annotation of the
phenotypes of BPD cases. After enrolling the largest col-
lection of BPD cases reported to date, we demonstrated
that HPO annotation enabled the characterisation of
clusters of BPD cases with similar phenotypes, which we
hypothesise have causal genetic variants in the same or
related genes. The use of HPO to facilitate research
within neurogenetics by comparing standard database
descriptions of diseases has been described previously
[18]. However, this is the first report of the application
of HPO to characterise individual case phenotypes and
to aid gene discovery through statistical cluster analysis.
The complex clinical characteristics of the 648 index
cases in the Stage 1 BRIDGE-BPD study reflect our desire
to enrol a comprehensive collection of cases with different
subgroups of disorders within BPD, including bleeding
of unknown origin. Previously reported collections havenger sequencing
ssification PLT, ×109/L MPV, fL and/or presence
of macrothrombocytes
Other MYH9-RD
characteristics
180 Macrothrombocytes None
184 10.1 None
262 10.2 None
164 NA None
53 11.1, Macrothrombocytes None
22 Macrothrombocytes None
46 Macrothrombocytes None
61 Macrothrombocytes None
319 9.8 None
149 10.1, Macrothrombocytes None
95 16.8, Macrothrombocytes None
99 13.6 None
244 NA None
26 Macrothrombocytes Döhle inclusions
act, deafness or renal pathology.
Table 4 Pathogenic and likely pathogenic variants identified in genes associated with autosomal recessive and X-linked recessive bleeding and platelet
disorders
Case Position Gene Ref Alt Genotype HGMD Effecta Haematological HPO terms Other HPO terms Classification:
Variant Phenotype
B200286 3:148881737 HPS3 G C C|C Yes Abnormal
splicing
Bleeding with minor or no trauma, subcutaneous haemorrhage, menorrhagia,
postpartum haemorrhage, impaired ADP-induced platelet aggregation,
impaired epinephrine-induced platelet aggregation, epistaxis, prolonged
bleeding after surgery, prolonged bleeding after dental extraction, increased
mean platelet volume.
Hypothyroidism,
visual impairment,
nystagmus, albinism.
PV Explained
B200412 3:148858819 HPS3 T TA T|TA No Frameshift Impaired epinephrine-induced platelet aggregation, bleeding with minor or
no trauma, subcutaneous haemorrhage, epistaxis, menorrhagia, prolonged
bleeding after surgery, abnormal dense granules.
Ocular albinism. LPV Possibly
explained
3:148876539 HPS3 G A G|A No W593a LPV
B200068 10:103827041 HPS6 C G C|G No L604V Increased mean platelet volume. Congenital cataract,
strabismus, maternal
diabetes.
LPV Possibly
explained
10:103827554 HPS6 C G C|G No L775V LPV
B200196 X:48542673 WAS C T T Yes T45M Thrombocytopenia, abnormal bleeding, decreased mean platelet volume,
abnormal platelet shape.
Recurrent infections. PV Explained
B200725 X:48544145 WAS T C C Yes F128S Monocytosis, neutrophilia, thrombocytopenia, leukocytosis, subcutaneous
haemorrhage, gastrointestinal haemorrhage.
PV Explained
B200443 X:138633272 F9 G A A Yes R191H Reduced factor IX activity, impaired ADP-induced platelet aggregation,
bleeding with minor or no trauma, spontaneous haematomas, abnormal
number of dense granules.
PV Partially
explained
B200452 X:154124407 F8 C G G Yes S2125T Reduced factor VIII activity, persistent bleeding after trauma, prolonged
bleeding after surgery, prolonged bleeding after dental extraction, bleeding
requiring red cell transfusion, impaired collagen-induced platelet
aggregation, bleeding with minor or no trauma, joint haemorrhage,
abnormal platelet shape, abnormal number of dense granules.
PV Partially
explained
B200772 X:154176011 F8 A G G No F692S Reduced factor VIII activity, bruising susceptibility, impaired ADP-induced
platelet aggregation, impaired collagen-induced platelet aggregation,
impaired thromboxane A2 agonist-induced platelet aggregation, impaired
ristocetin-induced platelet aggregation, impaired arachidonic acid-induced
platelet aggregation, impaired thrombin-induced platelet aggregation,
abnormal platelet granules, bleeding with minor or no trauma.
LPV Possibly
partially
explained
Alt: alternative; Ref: reference.
aEffect considered relative to the Consensus Coding Sequence (CCDS) for each gene.
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and collections linked by similar phenotypes such as
abnormal platelet number [38], platelet function [33] or
von Willebrand disease [21,39]. Thus, the BRIDGE-BPD
collection is unique in its size and diversity. In common
with previous collections, the BRIDGE-BPD cases were
predominantly females, who experienced more bleeding
symptoms than males because of obstetric and heavy
menstrual bleeding. There was marked heterogeneity in
PLT, MPV, platelet morphology, and particularly in LTA
platelet function test results, highlighting the diversity of
heritable platelet function disorders [33].
A striking finding from the Stage 1 BRIDGE-BPD study
was that a median of 7.5 HPO terms were required to
annotate the phenotype of each case. These comprised at
least one term from ‘abnormality of blood and blood-
forming tissue’, reflecting the study inclusion criteria.
However, 60% of cases also had HPO terms reflecting ab-
normality in other organ systems, even after removing
overlapping terms. We also observed a statistically signifi-
cant difference in the frequency of five haematological
HPO terms in cases with a nervous system abnormal-
ity compared to other cases (P = 0.001) reflecting more
frequent platelet function and morphology defects. This is
consistent with the existing literature indicating that
neurological and platelet function disorders often coincide
[34]. The statistically significant difference in the frequency
of the five haematological HPO terms between cases with
abnormal growth and those without (P = 8.12 × 10-6) arose
because of enrolment of a group of cases with growth de-
fects at a single centre. One potential criticism of Stage 1
of the BRIDGE-BPD study is that cases were recruited
from some centres with highly specialist interests, which
may reduce the wider applicability of the study findings.
This effect is illustrated by our finding of phenotypic asso-
ciations between haematological terms and both growth
and neurological terms arising from the specialist practice
at the University of Leuven. However, this effect is partially
offset by recruitment from the UK enrolment centres
which are more typical tertiary referral centres, and will
not occur in subsequent stages of the BRIDGE-BPD pro-
ject which will recruit more widely.
A further unique attribute of the BRIDGE-BPD meth-
odology is that it enables calculation of the closeness be-
tween groups of HPO terms annotated to different cases.
This provides a measure of phenotypic similarity between
cases and enables the definition of case subgroups to assist
the analysis of genotype data. We have provided proof of
principle of this approach by demonstrating low P values
for phenotypic similarity between BPD cases from the same
pedigrees and between unrelated cases with provisional
clinical diagnoses of syndromic BPD, in which both groups
are likely to share a causal genetic variant. This included
examples with known candidate genes (HPS and WAS)and with unknown genes (Gorham-Stout and Roifman
syndromes, pseudohypoparathyroidism type Ib).
We also evaluated phenotype similarity in groups of cases
sharing a rare coding variant in the same gene. The most
significantly similar group corresponded to cases harbour-
ing variants in ACTN1. Although this particular associ-
ation could be found through traditional regression-based
approaches against platelet count, the HPO approach al-
lows associations between genotypes and combinations of
any kind of HPO-encoded phenotypes to be discerned.
Here, an association was found between the presence of a
variant and two terms jointly - the ‘Thrombocytopenia’ and
‘Increased Mean Platelet Volume’ terms - while regression
analysis is typically performed trait by trait in a univariate
fashion. Certainly, standard regression methods cannot be
used to model heterogeneous combinations of data types
(binary, quantitative, categorical), nor can they account for
the hierarchical nature of ontologically encoded outcome
data. Furthermore, patient HPO data can be linked to data
in online human databases such as OMIM, and to model
system databases such as the Mouse Phenotype Ontology.
In future, this could be used to prioritise genes based on
the similarity of groups of cases to ontological phenotype
terms derived from the literature.
We assessed index cases harbouring variants in MHY9
who were not considered likely to have MYH9-RD by
the enrolling clinicians based on clinical evaluation. In
this group, the cases with PV or LPV in MYH9 displayed
a high degree of similarity whereas individuals with VUS in
MYH9 were not similar. Furthermore, the index cases with
PV or LPV in MYH9 were phenotypically different from
the index cases with VUS. This illustrates that HPO-based
clustering can reveal phenotype and genotype links that
cannot be made by enrolling clinicians in isolation but only
in combination with powerful methods for distinguishing
variants by predicted pathogenicity.
We also demonstrated potential limitations of this
approach arising from differences in phenotype coding
between and within enrolling centres. For example, two
pedigrees showed poor clustering by phenotype, with
phenotypic similarity P values of 0.42 and 0.33. In one of
these pedigrees, the lack of similarity between the two
members was because the index case had detailed pheno-
typic evaluation but the pedigree case consented only to
limited evaluation. In the other pedigree, the lack of simi-
larity was due to the marked difference in age at evalu-
ation. This illustrates how the age-dependence of HPO
terms such as bleeding symptoms may result in paediatric
cases clustering away from adult cases. The potential con-
founding effect caused by gender-specific HPO terms was
minimised by excluding these terms from calculation of
similarity scores. Despite these limitations, recruiting from
a heterogeneous set of centres is crucial to obtain the sam-
ple sizes required to achieve power for gene discovery.
Westbury et al. Genome Medicine  (2015) 7:36 Page 13 of 15The approach we have presented for computing simi-
larity scores relies on pre-selecting groups of cases based
on the presence of rare variants fulfilling certain criteria,
such as presumed mode of inheritance. Sometimes, only
a subset of the cases in a group will be explained by vari-
ants in the same gene, thus diluting the strength of
phenotypic similarity of the entire group. For ACTN1,
which was used to model similarity clustering analysis, the
effect of the dilution was minimal, but in other cases it
may play a larger role. The development of new methods
to offset this effect is a worthwhile area of future research.
Conclusions
We have demonstrated that HPO annotation of the large
and diverse BRIDGE-BPD collection enables the identifi-
cation of clusters of individuals with phenotypic similar-
ities who are likely to have causal genetic variants in the
same or related genes. Our international consortium has
enabled comparison of standardised phenotypic descrip-
tions among cases across the world, which improves
statistical power by increasing the size of case groups.
We have validated the methodologies developed for the
BRIDGE-BPD study, using BPD such as ACTN1-related
disorder, which have been newly reported since the start
of recruitment to our study collection. However, these ap-
proaches are equally applicable to disorders of unknown
genetic basis, in which cases are also expected to show
similarity of HPO terms. It is noteworthy that the cases in
the stage 1 BRIDGE-BPD study with PV or LPV in estab-
lished BPD genes together account for less than 10% of
the study collection. We anticipate that identification of
further case subgroups based on similarity of HPO terms
will be a powerful source of new gene discoveries in the
remainder of the study collection and among cases in the
ongoing enrolment programme. This gene discovery ap-
proach, pioneered here in bleeding and platelet disorders,
is broadly applicable to other rare disease groups.Additional files
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